SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Arena Pharmaceuticals (ARNA) -- Ignore unavailable to you. Want to Upgrade?

To: software salesperson who wrote (1461)3/30/2009 1:51:09 PM
From: scaram(o)uche  Respond to of 2274
 
Thanks, Sales.

Is he implying that the data was dropout-massaged?

Low-blow comment about similarity to placebo in other trials.

Best! Rick



To: software salesperson who wrote (1461)3/31/2009 11:59:11 AM
From: tuck  Read Replies (1) | Respond to of 2274
 
Derek Lowe echoes Birchenough and other negative analysts, with some extra color.

pipeline.corante.com

Cheers, Tuck



To: software salesperson who wrote (1461)3/31/2009 2:02:07 PM
From: scaram(o)uche  Respond to of 2274
 
Like Birchenough, I wouldn't trust Lief with squat. But????....

with confidence intervals not provided for 12 month echo data where a slightly
higher valvulopathy rate was seen with lorcaserin (2.7% vs. 2.3%)

He should be embarrassed to have even mentioned those numbers out of context. But, in context, the same population of patients?

18 months, 2.9 vs. 3.1

24 months, 2.6 vs. 2.7

He's clearly not objective.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News